Intelligent Bio Solutions Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Harry Simeonidis
- Full Time Employees
- 50
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 142 West 57th Street New York City NY United States of America 10019
- IPO Date
- Dec 23, 2020
- CIK
- 0001725430
- Website
- gbs.inc
- Similar Companies
- Business
- Intelligent Bio Solutions Inc. operates as a medical technology enterprise, pioneering rapid, non-invasive testing solutions. The company's flagship offering is its Intelligent Fingerprinting Drug Screening System, which revolutionizes portable drug testing by analyzing sweat from fingertips. This innovative system quickly identifies recent use of substances like opiates, cocaine, methamphetamine, and cannabis, delivering results typically within ten minutes. This hygienic and cost-effective approach offers a significant alternative to traditional testing methods, eliminating biohazardous waste and privacy concerns while enhancing efficiency for users. The company strategically targets safety-critical industries such as construction, logistics, and manufacturing, along with drug treatment organizations and law enforcement. Its revenue model is largely driven by recurring sales of high-margin consumable cartridges, reflecting a "razor-razorblade" business strategy that has led to consistent growth. In pursuit of expanding its market presence, the company submitted a 510(k) premarket notification for its drug screening system to the U.S. Food and Drug Administration in late 2024, although the process has since evolved to a request for a new resubmission due to its novel nature. Intelligent Bio Solutions has achieved record quarterly revenues and significantly expanded its global footprint, now serving over 480 active customer accounts across more than 24 countries. Established in 2016 and headquartered in New York, New York, Intelligent Bio Solutions Inc., formerly known as GBS Inc. until its name change in October 2022, continues to advance its biosensor platform with potential for broader diagnostic applications across various medical indications.
Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission
Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year
Comparing Establishment Labs (NASDAQ:ESTA) & Intelligent Bio Solutions (NASDAQ:INBS)
Aeon Global Health (OTCMKTS:AGHC) vs. Intelligent Bio Solutions (NASDAQ:INBS) Head-To-Head Review
Intelligent Bio Solutions Initiates Validation Study for Rapid Drug Screening Cartridge Targeting 70% Faster Results
Intelligent Bio Solutions Initiates Validation Study for Rapid Drug Screening Cartridge Targeting 70% Faster Results
Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified
Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market
Intelligent Bio Solutions Strengthens European IP Portfolio with Eighth Patent Grant
HealthEquity (NASDAQ:HQY) & Intelligent Bio Solutions (NASDAQ:INBS) Head to Head Comparison
Intelligent Bio Solutions Successfully Manufactures and Ships First Readers with New Partner, Accelerating Scale and Driving Gross Margin Expansion in Anticipation of Planned U.S. Entry
Intelligent Bio Solutions Partners with Bouygues UK, Part of Multi-Billion Dollar Global Construction Giant Bouygues Construction, for UK Drug Testing Rollout
Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year
Intelligent Bio Solutions Expects to Report Fiscal Second Quarter 2026 Revenue Growth of Approximately 48% Year-Over-Year, Surpassing $2 Million in Total Revenue for First Half of Fiscal Year
Short Interest in Intelligent Bio Solutions Inc. (NASDAQ:INBS) Increases By 187.3%
Intelligent Bio Solutions Initiates Additional Clinical Studies for FDA 510(k) Submission Supporting Planned Entry into Multi-Billion Dollar U.S. Market
Intelligent Bio Solutions Announces Closing of $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
INBS Stock Surges 132.4% on New Manufacturing Partnership
Stock Market Today: S&P 500, Dow Futures Gain On The First Trading Day Of 2026— Baidu, Rubico, Intelligent Bio Solutions In Focus
Intelligent Bio Solutions Announces $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules